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DMD is a devastating genetic disorder that starts with muscle weakness in early childhood and is ultimately lethal due to progressive muscle loss 1 . In skeletal muscles, the major DMD isoform consists of 79 exons and encodes a 427 kD Dystrophin protein 2, 3 . Dystrophin is a structural protein that links the actin cytoskeleton to the sarcolemma and extracellular matrix to protect muscle against degeneration 7 . The mdx mouse carries a nonsense mutation in exon 23 (e23) of the orthologous Dmd gene and has been an invaluable a model for studying DMD 4 . This model also serves as a benchmark for evaluating pre-translational studies 8 . Currently, the most promising pre-translational approach is using the CRISPR technology to delete the mutated exon to restore reading frame 9, 10 . However, CRISPR mediated therapies will likely require years of evaluation for safety due to potentially unexpected off target effects among highly heterogeneous patient genomes. Therefore, improving methods currently under development and finding new strategies remain of high priority 11 .
Because exons in the middle of the DMD locus are largely dispensable 12 , current methods are aimed to have internally truncated Dystrophin expressed via various means 13, 14 . An estimated 80-90% of DMD patients can benefit from single or multiple exon skipping events to restore the reading frame and express internally truncated Dsytrophin 15 . Based on this, the use splice-site blocking anti-sense oligonucleotides to force exclusion of mutated exon to restore reading frame is in clinical trials 16 . Disease progression of DMD is also accompanied by chronic inflammation, and various antiinflammatory treatments have been used to improve muscle pathology 17 . IL4 and its closely related IL13 are anti-inflammatory interleukins 18 and both have been shown to enhance myoblast fusion in vitro 19, 20 . IL4 also acts through fibro-adipogenic progenitors to promote muscle regeneration in vivo 21 . We therefore hypothesize that IL4 or IL13 treatment should have dual benefits of suppressing inflammation and enhancing muscle regeneration in the mdx mouse.
To examine the effect of IL4 and IL13 in the mdx mouse, we injected each into the tibialis anterior (TA) muscles of the right leg, and PBS into the left TA muscles of the same animals as controls (Fig. 1a) . Because mdx mice develop pathology at ~3 weeks after birth 4 , we chose early intervention at week 2 after birth (2 µg of IL4 or IL13 per kg body weight (2 µg/kg) per TA muscle). Consistent with their anti-inflammatory role, IL4-and IL13-treated muscles displayed fewer interstitial cells and infiltrating F4/80-positive (F4/80 + ) macrophages, compared to control muscles ( Fig. 1b-d) . Unexpectedly, when we examined Dystrophin expression using the MANDRA1 antibody against its C-terminus (a.a. 3667-3671, encoded in exon 77) ref. 22 , we found that IL4-and IL13-treated mdx TA muscles had significantly more MANDRA1 + myofibers (>20%) than control mdx muscles (0.6%; Fig. 1e ,f). Western blot analyses confirmed increased levels of Dystrophin in IL4-and IL13-treated mdx muscle lysates (Fig. 1g,h ). Using Evans Blue Dye (EBD) to assess membrane permeability, we determined that IL4-and IL13-treated samples had reduced EBD + muscle fibers, reflecting an improved myofiber integrity (Fig.   1i ,j). Pharmacokinetic assessment of IL4 and IL13 ( Supplementary Fig. S1a ,b) revealed the strongest effects (based on MANDRA1 + myofibers) of both ILs was at 2 µg/kg in the 2-and 3-week age groups, while a decreased effect at 5 µg/kg was noted. Treatment proved less effective as mice matured (weeks 4-10). Thus early intervention by IL4 and IL13 can reduce inflammatory infiltration and restore Dystrophin in mdx TA muscles.
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Using RT-PCR, we found multiple spliced forms that exclude the mutated exon and predict contiguous reading frame in IL4/13-treated mdx muscles (Fig. 2a) Fig. S2 ).
Accompanying Dystrophin production, Dystrobrevin and Syntrophin were also restored at the sarcolemma of treated mdx muscles ( Fig. 2e-g ), suggesting formation of functional complex. Thus, IL4 and IL13 induce exon skipping to restore Dystrophin and its associated proteins to the mdx sarcolemma.
Transcriptomic analyses revealed 200 up-regulated and 254 down-regulated genes common in IL4-and IL13-treated mdx muscles, compared to PBS-treated mdx muscles ( Supplementary Fig. S3 ). Forty-eight of these genes showed a reversed trend of expression from that in DMD patients and animal models [24] [25] [26] [27] [28] , supporting an improvement. As expected from known actions of IL4 and IL13, a larger fraction of skeletal muscle tissue/fiber developmental genes shows upregulation, while an increased fraction of inflammatory genes is repressed. Fig. S4 ) in these muscle groups. To determine whether muscle strength and resistance were improved, we assessed forelimb weightlifting capability ( Fig. 3i ) and used the Kondziela's inverted test for muscle resistance and strength ( Fig. 3j ) 30, 31 . As expected, IL4-Fc treated group performed better on both tests than the PBS-treated group.
We next examined whether IL4 and IL13 acted directly on mdx myoblasts to induce Dmd exon skipping. Using a modified myoblast recruitment protocol 19 , we isolated myoblasts from ~2 weeks old mdx mice and treated them with IL4 or IL13 for 48 h in growth media. These cells were then exposed to differentiation media for 72 h and plateaued at 5 and 10 ng/ml, respectively, without a negative impact up to 100 ng/ml ( Supplementary Fig. S5c ), contrasting to their narrow effective dose in vivo. We also confirmed in our culture the absence of the PDGFRa ! fibro-adipogenic progenitor ( Supplementary Fig. S5d ), an IL4 target cell type that indirectly enhances muscle regeneration 21 .
qRT-PCR profiling of key signaling components of IL4 and IL13 revealed that (except for Tyk2) IL4Rα, Jak1, Jak2, Jak3, and Stat6 are expressed at higher levels in 2- Fig. S7 ), suggesting that exonskipping of the mutant Dmd locus is not the consequence of a global splicing change.
As we applied IL4 to mdx cells at the myoblast growth stage and observed Dystrophin reversion in differentiated myotubes, we asked whether IL4 treatment could have a longterm effect. For this, we obtained reserve cells 32 , similar to quiescent muscle stem cells, from differentiated mdx cultures that were initially un-treated or treated with IL4 8 ( Supplementary Fig. S8a,b) . We then re-activated them to growing myoblasts and differentiated them again, all the while without adding IL4. Intriguingly, IL4-treated mdx myoblasts retained Dystrophin reversion phenotype in the second round of differentiation ( Supplementary Fig. S8c,d ). This predicts that IL4/13 treatment in vivo may also maintain myofibers with restored Dystrophin over a long period. Indeed, 30 weeks after a single intramuscular injection of IL4 or IL13, considerable MANDRA1+ myofibers were found ( Supplementary Fig. S8e-g ). Altogether, we conclude that IL4, and likely IL13, acts directly on mdx myoblasts to induce a long-term Dystrophin reversion phenotype.
To begin evaluating the viability of IL4/13 as a treatment for DMD, we explored whether the exon skipping/Dystrophin restoration activity of IL4 and IL13 was effective on DMD patient-derived immortalized cell lines 33 . We chose two lines that were derived from juveniles and represented frequently deleted genomic region of DMD, Del.45 and Del.45-51. They were treated with IL4 or IL13, induced to differentiated, and assayed for Dystrophin. For the Del.45 line, MANEX4850A 22 were used for assessment ( (Fig. 4f ).
Finally, we tested whether xenotransplantation of IL4-treated Del.45 and Del.45-51 cells into cryodamaged TA muscles of NRG mouse would yield Dystrophin + myofibers.
One month after transplantation, we found human-specific Spectrin + myofibers derived 9 from transplanted Del.45 ( Fig. 4g) and Del.45-51 cells (Fig. 4i) regardless of treatments.
Within the Spectrin + area, significantly more DYS2 + myofibers were found in IL4-treated, compared to non-treated Del.45 (Fig.4g, h ) and Del.45-51 (Fig.4i, j) cells. Thus,
IL4-treated DMD cell lines show restored Dystrophin expression in vivo.
Our study defines a new role for IL4 and IL13 and expands their functional repertories beyond immune responses 18 , myoblast recruitment/muscle regeneration [18] [19] [20] , and brown adipogenesis 34 . Interestingly, we found IL4/13 treatment most effective on juvenile animals and myoblasts. We propose IL4/13 utilizes a developmental window to affect long-term changes in pre-mRNA splicing pattern. As IL4 induces exon-skipping events around the middle exons of the Dmd/DMD loci, it may have a wide-range of application to a larger cohort of patients than the specific designs needed for anti-sense oligos or CRISPR to each patient. In contrast to current strategies employing transgenes, stem cells, oligonucleotides, and CRISPR, IL4 and IL13 are natural biomolecules and the safety of IL4 has been established in clinical trials 5, 6 . How IL4/IL13 induces exon skipping of the mutated Dmd locus in mouse and human patient myoblasts remains an intriguing open question to be answered. We therefore urge clinical teams specialized in DMD to consider fast track the process and begin trials of applying our approach to patients.
Methods

(Additional protocols and reagents are detailed in supplementary information).
Animals and Treatments
C57BL/10, mdx and NRG mice (Jackson Laboratory) were housed in a pathogen-free facility. All animal experiments were approved by IACUC. PBS, IL4 and IL13 (R&D Systems) were delivered intramuscularly. IL2-Fc, IL4-Fc (AdipoGen Life Sciences), and
Evans Blue dye (EBD, Sigma) were delivered intraperitoneally. NRG mice were used as transplantation recipients for human DMD myoblasts. Age of animals and muscle sample harvest time line are specified in the text and legends.
Processing of muscle samples
Muscle samples were cryosectioned at 8 µm. For histology or immunofluorescence, sections were fixed by 4% paraformaldehyde (in PBS), and subjected to hematoxilin & eosin (Surgipath) staining or primary and secondary antibody incubation, respectively, as described 35 . For visualizing EBD staining, sections were fixed in cold acetone (-20°C).
Antibody sources and dilutions are detailed in supplementary information.
Western blotting
Muscle protein extracts were prepared as described 35 and resolved by SDS-PAGE (4-20% gradient gel, Bio-Rad), followed by Western blotting using specified antibodies and ECL detection (GE Healthcare).
Primary myoblast culture
Primary myoblasts were isolated as described 18 Assay kit (Promega) was used.
RNA extraction, RT-PCR, nested RT-PCR and quantitative PCR (qPCR)
Total RNAs from TA samples and cultured cells were extracted using TRIzol reagent (Invitrogen) and used for RT-PCR, qRT-PCR, or RNA-seq. Exon skipped Dmd transcripts were detected using nested primers to detect in-frame splicing events. PCR products were resolved by electrophoresis on a 2% agarose gel. qPCR was performed using the BioRad CFX96 Real-Time System with CFX manager.
Muscle strength
Kondziela's test and a weightlifting test were performed to evaluate strength, resistance, and exercise abilities 30, 31 . The scores were calculated and normalized by the body weight.
Human DMD immortalized cell culture and transplantation
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Human DMD cell lines were maintained in Skeletal Muscle Cell Growth Medium (Promocell). IL4 and IL13 (R&D Systems) treatment was the same as for mdx myoblasts.
For transplantation, 5×10 5 cells were used for injection into TA muscles of NRG immunodeficient mice 33 .
RNA sequencing and bioinformatics
For each RNA-seq data set, 3 independent samples were used. Purity and integrity of RNA were assessed by nanodrop ND-100 (Nanodrop) and Bioanalyser 2100 (Agilent).
cDNA libraries were constructed using Illumina TruSeq RNA Library Prep Kit v2, and sequenced by HiSeq2000; 100-nucleotide single read and ~40 million reads per sample.
Normalized read counts (in FPKM) were calculated using Bowtie2 v 2.0.6, TopHat v 2.0.7, and Cufflinks version 2.02. Functional analysis was done by DAVID functional annotation clustering and for up-regulated and down-regulated genes with a fold change of ≥ 2 and enrichment score of ≥ 1. Quantas pipeline was used for analysis of alternative splicing information from RNA-Seq data.
Image Acquisition and Processing
All images were taken by AxioCam mounted on an Axioscope. Signal intensities were adjusted only when necessary for presentation according to the ORI data processing guidelines. No quantification statements were made based on difference in fluorescence intensity.
Quantification and statistical Analyses
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Results are expressed as means ± SEMs, unless otherwise specified. Statistical analyses were performed by Excel using t-test. A p-value less than 0.05 is considered significant.
Accession codes
All sequencing data have been deposited at NCBI Sequence Read Archive (SRA), with assigned project number PRJNA414242 (to be released). 
Figure Legends
